胰腺癌仍然是最致命的癌症之一，死亡率极高，预计病例数将随着时间的推移而稳步增加。由于其免疫抑制和促纤维增生表型，胰腺癌对传统癌症治疗方案（如化疗和放疗以及商业化免疫治疗）难以治疗。由于这些原因，迫切需要开发一种创新的治疗方案来克服胰腺肿瘤微环境（TME）带来的这些挑战。本综述旨在总结过去十年来溶瘤腺病毒 (oAd) 工程和治疗用途（单一疗法或联合疗法）的演变，以克服这些障碍，从而对促结缔组织增生性和免疫抑制性胰腺癌发挥有效的抗肿瘤作用。版权所有 © 2023 . 爱思唯尔 B.V. 出版

Pancreatic cancer remains one of the deadliest cancers with extremely high mortality rate, and the number of cases is expected to steadily increase with time. Pancreatic cancer is refractory to conventional cancer treatment options, like chemotherapy and radiotherapy, and commercialized immunotherapeutics, owing to its immunosuppressive and desmoplastic phenotype. Due to these reasons, development of an innovative treatment option that can overcome these challenges posed by the pancreatic tumor microenvironment (TME) is in an urgent need. The present review aims to summarize the evolution of oncolytic adenovirus (oAd) engineering and usage as therapeutics (either monotherapy or combination therapy) over the last decade to overcome these hurdles to instigate a potent antitumor effect against desmoplastic and immunosuppressive pancreatic cancer.Copyright © 2023. Published by Elsevier B.V.